Rallybio Corp
RLYB0.540USD
+0.005+0.97%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
22.48MCap. mercado
PérdidaP/E TTM
Más Datos de Rallybio Corp Compañía
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Información de la empresa
Símbolo de cotizaciónRLYB
Nombre de la empresaRallybio Corp
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoDr. Stephen (Steve) Uden, M.D.
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 29
Dirección234 Church Street
CiudadNEW HAVEN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal06510
Teléfono12038593820
Sitio Webhttps://rallybio.com/
Símbolo de cotizaciónRLYB
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoDr. Stephen (Steve) Uden, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Wendy K. Chung, M.D., Ph.D.
Dr. Wendy K. Chung, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
--
--
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
FY2024
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
636.00K
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Viking Global Investors LP
10.08%
Johnson & Johnson Innovation-JJDC, Inc.
8.74%
5AM Ventures
8.72%
New Leaf Venture Partners LLC
7.93%
TPG Capital, L.P.
7.28%
Other
57.25%
Accionistas
Accionistas
Proporción
Viking Global Investors LP
10.08%
Johnson & Johnson Innovation-JJDC, Inc.
8.74%
5AM Ventures
8.72%
New Leaf Venture Partners LLC
7.93%
TPG Capital, L.P.
7.28%
Other
57.25%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
35.25%
Investment Advisor/Hedge Fund
15.11%
Investment Advisor
13.40%
Private Equity
7.28%
Individual Investor
4.16%
Hedge Fund
3.84%
Research Firm
0.25%
Pension Fund
0.03%
Other
20.68%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
146
33.40M
80.26%
-5.22M
2025Q1
153
34.13M
82.02%
-4.90M
2024Q4
156
33.77M
81.40%
-4.07M
2024Q3
163
33.31M
80.30%
-4.27M
2024Q2
165
34.52M
83.29%
-5.35M
2024Q1
149
33.11M
86.93%
-2.72M
2023Q4
143
34.47M
90.96%
-619.59K
2023Q3
138
35.89M
94.72%
-1.76M
2023Q2
134
36.21M
95.77%
-44.55K
2023Q1
130
35.24M
93.30%
-1.12M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Viking Global Investors LP
4.19M
10.08%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.64M
8.74%
--
--
Mar 31, 2025
5AM Ventures
3.63M
8.72%
--
--
Mar 31, 2025
New Leaf Venture Partners LLC
3.30M
7.93%
--
--
Mar 31, 2025
TPG Capital, L.P.
3.03M
7.28%
--
--
Mar 31, 2025
Pivotal Bioventure Partners Investment Advisor LLC
2.40M
5.78%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.79M
4.29%
+18.52K
+1.05%
Mar 31, 2025
abrdn Inc.
1.73M
4.15%
--
--
Mar 31, 2025
Almitas Capital LLC
1.30M
3.13%
+2.46K
+0.19%
Mar 31, 2025
The Vanguard Group, Inc.
971.93K
2.34%
+46.41K
+5.01%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Ver más
DFA Dimensional US Core Equity Market ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
iShares Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
